Preclinical trials

PRECLINICAL DATA

Cyproheptadine : Antagonist of 5HT2 and 5HT1C receptors used in the treatment of allergy

Prazosin : Antagonist of alpha1-adrenergic receptors used in the treatment of arterial high blood pressure

Addiction to alcohol:

Effects of the combination on the alcohol intake and on preference to alcohol.

Cyproheptadine + Prazosin in combination (KT-110 of Kinnov Therapeutics) reverses preference to alcohol and induces a strong alcohol aversion. Other studies show better efficacy of KT-110 than available products.

Addiction to nicotine:

Effects of KT-110 on behavioral sensitization to nicotine.

Nicotine induces an hyperactivity that becomes more marked after the 2nd and 3rd injections (Behavioral Sensitization).KT-110 antagonizes behavioral sensitization induced by nicotine

Patents

KINNOV HOLDS 3 FAMILIES OF PATENTSBV06, BV06BIS AND BV06TER

BV06 (2004)

BV06BIS (2010)

Protection of combinations and compositions for addiction to alcohol treatment

Granted in France

Granted in Europa

Granted in China

Granted in Australia

Granted in USA

The most important patent (BV06BIS) has been recognized by the major countries with a significative addiction market

Essential point: We have obtained a protection not only on the indication but also on the composition. Consequently, the association is protected whatever the indication.

BV06TER

Protection of combinations and compositions for addiction to other drugs – tabacco…

Granted in France

Granted in Russia

Granted in Ukraine

Co-funded by the horizon 2020 programme of the European Union

About us

Kinnov Therapeutics is dedicated to the R&D of innovative therapies against addiction.
Supported by experienced scientists in the drug discovery and development, we have identified the key receptors of addiction. KT-110, our first-in-class lead composition, enters phase 2 clinical trial for alcohol addiction.